SEC Form 4 · accession 0001104659-26-105690
Orchestra BioMed Holdings, Inc. · OBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Hochman
Officer — See Remarks · Director
Period of report
Sep 3, 2026
Accepted (ET)
Sep 8, 2026 · 8:15 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001814114
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")F1 | Sep 3, 2026 | P | 10,000 | $4.79 | A | 1,070,746 | D | |
| Common Stock | holding | — | — | — | 436,199 | I | By the DPH 2008 Trust | |
| Common Stock | holding | — | — | — | 2,000 | I | By the Solomon Ascher Hochman 2019 Trust | |
| Common Stock | holding | — | — | — | 2,000 | I | By the Hannah Hochman 2019 Trust | |
| Common Stock | holding | — | — | — | 2,000 | I | By the Judah Herman Hochman 2019 Trust | |
| Common Stock | holding | — | — | — | 3,140 | I | By the NSH 2008 Family Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.73 to $4.79. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Remarks
Chief Executive Officer and Chairperson